Atea Pharmaceuticals (AVIR) Interest & Investment Income (2020 - 2022)
Historic Interest & Investment Income for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to $5.6 million.
- Atea Pharmaceuticals' Interest & Investment Income rose 1086274.51% to $5.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $11.2 million, marking a year-over-year increase of 511074.77%. This contributed to the annual value of $25.5 million for FY2024, which is 1277.72% down from last year.
- According to the latest figures from Q4 2022, Atea Pharmaceuticals' Interest & Investment Income is $5.6 million, which was up 1086274.51% from $4.4 million recorded in Q3 2022.
- Atea Pharmaceuticals' 5-year Interest & Investment Income high stood at $5.6 million for Q4 2022, and its period low was $7000.0 during Q3 2020.
- Moreover, its 3-year median value for Interest & Investment Income was $53000.0 (2021), whereas its average is $1.0 million.
- Within the past 5 years, the most significant YoY rise in Atea Pharmaceuticals' Interest & Investment Income was 1086274.51% (2022), while the steepest drop was 6896.55% (2022).
- Over the past 3 years, Atea Pharmaceuticals' Interest & Investment Income (Quarter) stood at $9000.0 in 2020, then surged by 466.67% to $51000.0 in 2021, then soared by 10862.75% to $5.6 million in 2022.
- Its Interest & Investment Income was $5.6 million in Q4 2022, compared to $4.4 million in Q3 2022 and $1.1 million in Q2 2022.